The three-day conference is expected to bring together more than 3,000 physiotherapists, clinicians, researchers, academicians, and students
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter
The improved score reflects a stronger ESG profile for the Ahmedabad-based drugmaker
The FDA clearance of Zeto New Wave marks the company’s third cleared device, alongside Zeto WR19 and Zeto ONE
The presentations will showcase previously undisclosed data highlighting the expanding potential of Actinium’s Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies
The initiative is aimed at strengthening the district-level screening and chronic disease management infrastructure
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
The enhanced allocation will be directed toward expanding healthcare infrastructure, increasing patient capacity, and widening acces
Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker
Scholarships, research grants and industry mentorship framework aim to strengthen India’s pharma R&D ecosystem
20 among them to receive $20,000 grants
The results were consistent across both the 10 mg and 40 mg treatment arms
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
